Drug Trial Radar · NCT05071300
A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
Last checked: Nov 20, 2026Latest source record: Dec 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
151
Actual
Start
Jan 4, 2022
Primary completion
Aug 2029
Study completion Aug 2029
Sponsor
- Lead sponsor
- Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
- Sponsor type
- Industry
- First posted
- Oct 8, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and tolerability of extended dosing with eplontersen in participants with hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN).
Conditions
- Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
Interventions
EplontersenDrug
Eplontersen will be administered by SC injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Platelet CountTime frame: Baseline to Week 181
- Number of Participants With Clinically Significant Changes From Baseline in Renal FunctionTime frame: Baseline to Week 181
- Number of Participants with Clinically Significant Changes from Baseline in TransaminasesTime frame: Baseline to Week 181
- Change From Baseline in Adverse EventsTime frame: Baseline to Week 181
- Change From Baseline in Number of Concomitant Medications UsedTime frame: Baseline to Week 181
- Number of Participants With Clinically Significant Changes From Baseline in Vital SignsTime frame: Baseline to Week 181
- Change From Baseline in Body WeightTime frame: Baseline to Week 181
- Number of Participants With Clinically Significant Changes From Baseline in Physical Examination FindingsTime frame: Baseline to Week 181
- Number of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory TestsTime frame: Baseline to Week 181
- Number of Participants With Clinically Significant Changes From Baseline in Electrocardiogram (ECG) ParametersTime frame: Baseline to Week 181
- Number of Participants With Clinically Significant Changes From Baseline in Thyroid Panel TestsTime frame: Baseline to Week 181
- Number of Participants With Clinically Significant Changes From Baseline in Coagulation TestsTime frame: Baseline to Week 181
- Number of Participants With Clinically Significant Changes From Baseline in Inflammatory Panel TestsTime frame: Baseline to Week 181
- Number of Participants With Clinically Significant Changes From Baseline in Complement and Immunogenicity TestsTime frame: Baseline to Week 181
Locations
33 sites in 13 countries. Site status is shown where the registry gives one.
Mayo Clinic
Scottsdale, Arizona
Indiana University Health University Hospital
Indianapolis, Indiana
Johns Hopkins University Neurology Research Office
Baltimore, Maryland
Boston University School of Medicine
Boston, Massachusetts
The Neurological Institute of New York
New York, New York
University of North Carolina Hospitals - Neurology Clinic
Chapel Hill, North Carolina
Oregon Health and Science University
Portland, Oregon
University of Washington Medical Center
Seattle, Washington
Hospital Italiano de Buenos Aires
Buenos Aires, Argentina
Instituto Fleni
Buenos Aires, Argentina
Hospital El Cruce
San Juan Bautista, Argentina
Perron Institute for Neurological and Translational Science
Murdoch, Western Australia, Australia
Universidade Estadual de Campinas
Campinas, Brazil
Instituto de Neurologia de Curitiba
Curitiba, Brazil
Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto
São Paulo, Brazil
Hospital Universitario Clementino Fraga Filho
Botafogo, Rio de Janeiro, Brazil
Vancouver General Hospital
Vancouver, British Columbia, Canada
Toronto General Hospital
Toronto, Ontario, Canada
The Cyprus Institute of Neurology and Genetics
Égkomi, Cyprus
Hôpital de la Timone
Marseille, France
Centre Hospitalier Universitaire de Toulouse
Toulouse, Haute-Garonne, France
Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Fondazione Istituto Neurologico Carlo Besta
Milan, Italy
Fondazione IRCCS Policlinico San Matteo
Pavia, Italy
Centro Hospitalar Universitário Lisboa Norte - Hospital De Santa Maria
Lisbon, Portugal
Centro Hospitalar Universitário do Porto - Hospital Geral de Santo Antonio
Porto, Portugal
Hospital Clínico San Carlos
Madrid, Spain
Hospital Son Llàtzer
Palma de Mallorca, Spain
Norrlands Universitetssjukhus
Umeå, Sweden
China Medical University Hospital
Taichung, Taiwan
National Taiwan University Hospital
Taipei, Taiwan
Taipei Veterans General Hospital
Taipei, Taiwan
Chang Gung Memorial Hospital
Taoyuan, Taiwan
Istanbul Üniversitesi - Istanbul Tip Fakültesi
Istanbul, Turkey (Türkiye)
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.